| Popis: |
Hematopoietic stem cells (HSC) have the ability to repopulate the hematopoietic system by differentiating into all of the necessary erythroid, lymphoid, and myeloid lineages. Due to this rare ability, HSC are used as therapeutic agents in the treatment of malignant and benign diseases of the blood forming and immune systems. There have been many advances in the area of clinical HSC research, but the availability of suitable cells for transplantation still remains a major limiting factor. HSC can be isolated from three different sources: umbilical cord blood (CB), bone marrow, and mobilized peripheral blood. CB is currently the preferred source because it has been shown to have a lower risk of graft versus host disease (GVHD), presumably due to its immunological naivete. However, because the volume of CB is limited, each umbilical cord has only enough cells to successfully transplant a small child. In order to transplant an adult, the HSC from CB must be expanded ex vivo. The expansion must be performed in a manner to ensure that the HSC not only differentiate along appropriate hematopoietic lineages, but also self-renew, leaving undifferentiated stem cells in the expanded culture. In order to expand these very specific cell types, an optimized serum-free medium and cytokine cocktail are needed. To this end, Stemline Hematopoietic Stem Cell Expansion Media were developed for the expansion of HSC. They are serum-free media that allow for expansion of both differentiated and undifferentiated HSC. StemlineTM and StemlineTM II are both able to expand HSC from CB, bone marrow, and mobilized peripheral blood. In bench-scale and clinical-scale expansions, both media have |
